Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questran second advisory committee divided on OTC switch recommendation.

This article was originally published in The Tan Sheet

Executive Summary

QUESTRAN ADVISORY COMMITTEE EVENLY SPLIT ON OTC SUITABILITY after a reconsideration of Bristol-Myers Squibb's application to switch its Questran (cholestyramine) and Questran Light from prescription to OTC status for the treatment of hypercholesterolemia. At a May 13 meeting in Bethesda, Md., members of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committee voted five to five with one abstention on the suitability of the switch.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS087074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel